Previous close | 4.1000 |
Open | 4.3000 |
Bid | 4.0600 x 1600 |
Ask | 4.0800 x 1600 |
Day's range | 4.0500 - 4.5000 |
52-week range | 1.6300 - 8.8300 |
Volume | |
Avg. volume | 2,649,153 |
Market cap | 462.097M |
Beta (5Y monthly) | 1.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6400 |
Earnings date | 03 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.80 |
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Study of FT819 Off-the-shelf, CD19-targeted, iPSC-derived CAR T-cell Therapy for Systemic Lupus Erythematosus SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.